UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: April 2017
Commission file number: 001-37846
CELLECT BIOTECHNOLOGY LTD.
(Translation of registrant's name into English)
23 Hata’as Street
Kfar Saba, Israel 44425
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F xForm 40-F¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):¨
This Report of Foreign Private Issuer on Form 6-K of the Registrant consists of the press release issued by the Registrant on April 3, 2017, entitled “Cellect Receives Notice of Intention to Grant from European Patent Office for Patent Protecting Company’s Technology in Multiple Indications”, which is attached hereto as Exhibit 99.1.
Exhibit No.
| 99.1 | Press Release issued by Cellect Biotechnology Ltd. on April 3, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | Cellect Biotechnology Ltd.
(Registrant)
By /s/ Eyal Leibovitz
|
| | | Name: Eyal Leibovitz Chief Financial Officer |
Date: April 3, 2017
